Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xilio Therapeutics ( (XLO) ) has provided an update.
On March 9, 2026, Xilio Therapeutics posted an updated corporate investor presentation outlining its strategy to leverage clinically validated masking technology to develop tumor-selective immuno-oncology candidates, including vilastobart, efarindodekin alfa and next-generation bispecific and multi-specific T cell engager programs. The company highlighted key development timelines for its pipeline, including an IND submission for XTX501 in mid-2026 and initial Phase 1 data in the second half of 2027, as well as anticipated milestone and option payments from AbbVie and Gilead, which, together with $137.5 million in estimated year-end 2025 cash and a recent $40 million follow-on offering, are expected to support continued advancement of its portfolio and strengthen its financial and competitive position in the I-O space.
The most recent analyst rating on (XLO) stock is a Hold with a $0.59 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.
Spark’s Take on XLO Stock
According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.
The score is primarily held back by weak financial fundamentals (large losses, ongoing cash burn, and negative equity) despite strong recent revenue growth. Technicals are mixed with a weak longer-term trend but neutral-to-stable near-term momentum. Corporate events improve the outlook by extending cash runway into 2027, while valuation is constrained by a negative P/E and no dividend data.
To see Spark’s full report on XLO stock, click here.
More about Xilio Therapeutics
Xilio Therapeutics, Inc. is a biotechnology company focused on developing tumor-selective immuno-oncology therapies using a proprietary masking technology to concentrate anti-tumor activity within the tumor microenvironment. Its pipeline includes masked antibodies, cytokines, bispecifics and multi-specific T cell engagers targeting solid tumors, supported by strategic collaborations with AbbVie, Gilead and Roche that provide both validation and non-dilutive funding.
Average Trading Volume: 447,222
Technical Sentiment Signal: Sell
Current Market Cap: $38.93M
Learn more about XLO stock on TipRanks’ Stock Analysis page.